DelveInsight’s “Exosomes Pipeline Insight 2026” report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Exosomes pipeline landscape. It covers the Exosomes Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Exosomes Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Exosomes Pipeline? @ https://www.delveinsight.com/sample-request/exosomes-pipeline-insight
Key Takeaways from the Exosomes Pipeline Report
Want to know which companies are leading innovation in Exosomes? @ Exosomes Clinical Trials Assessment
The Exosomes Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Exosomes Pipeline Report also highlights the unmet needs with respect to the Exosomes.
Exosomes Overview
Exosomes are small extracellular vesicles (≈40–160 nm) released by most cell types through the fusion of multivesicular bodies with the plasma membrane, which liberates intraluminal vesicles into the extracellular space. They are widely present in biological fluids such as blood, urine, breast milk, and semen, and can be taken up by distant cells. Through the transfer of bioactive cargo, exosomes play a crucial role in cell–cell communication and can influence disease progression. Their contents including proteins, lipids, nucleic acids, amino acids, and metabolites reflect their cell of origin and are shaped during their biogenesis in the endosomal pathway. Owing to these properties, exosomes are being actively explored for diagnostic and therapeutic applications, particularly in drug discovery. They are commonly isolated using techniques such as differential centrifugation and polymer-based precipitation.
Exosomes Emerging Drugs Profile
Capricor’s CAP-1002 consists of cardiosphere-derived cells (CDCs), a type of cardiac progenitor cell originally discovered in the laboratory of its scientific founder, Eduardo Marbán. These CDCs have been extensively studied, with over 100 peer-reviewed publications and clinical administration in more than 200 patients across multiple trials. CAP-1002 works by releasing exosomes, small vesicles that influence immune responses and promote tissue repair. These exosomes are primarily taken up by macrophages and T cells, triggering regenerative processes and modulating immune activity. The therapy is currently in the registration stage for the treatment of Duchenne Muscular Dystrophy.
Debamestrocel (NurOwn) consists of autologous bone marrow–derived mesenchymal stem cells (MSCs) that are cultured to secrete elevated levels of neurotrophic factors, supporting neuronal survival and repair. These MSC-NTF cells combine the immunomodulatory effects of MSCs with enhanced neurotrophic activity, partly mediated through exosome-based delivery of factors such as GDNF. The therapy is manufactured from a patient’s own MSCs, expanded and differentiated ex vivo without genetic modification, and then re-administered. It is currently in Phase III development for the treatment of Amyotrophic Lateral Sclerosis, with additional programs in multiple neurological disorders at earlier stages.
AGLE-102 is an allogeneic extracellular vesicle (EV) therapy derived from mesenchymal stem cells obtained from healthy donors. It consists of MSC-derived vesicles that deliver proteins, genetic material, and regenerative factors to support repair in damaged tissues. The therapy is currently in Phase I/II development for the treatment of burns and Epidermolysis Bullosa Dystrophica, and is also being explored at the preclinical stage for Graft-versus-Host Disease.
RioMSK001 is an innovative therapeutic candidate developed by Rion for musculoskeletal disorders. It is designed to address degenerative joint conditions with a focus on improving function and reducing disease burden. According to the company’s pipeline, the therapy is currently in early clinical evaluation. It is in Phase I development for the treatment of Knee Osteoarthritis.
HEPATOSOME is an investigational therapy being developed by ExoStemTech. It is designed as a novel approach targeting liver-related disorders through advanced therapeutic mechanisms. The candidate is currently undergoing early-stage research and evaluation. At present, it is in preclinical development for the treatment of Liver Fibrosis.
If you’re tracking ongoing Exosomes Clinical trials, this press release is a must-read @ Exosomes Treatment Drugs
The Exosomes Pipeline report provides insights into:-
Exosomes Companies
Capricor Therapeutics, BrainStorm Cell Therapeutics, Aegle Therapeutics, EXO Biologics, RION, S&E bio, Shine-On Biomedical Co., Ltd., ImmVira, ILIAS Biologics, Secretome Therapeutics, VesiCURE Therapeutics, Everzom, Brexogen, ShiftBio, Conveyxo, Exogenus Therapeutics, Coya Therapeutics, VivaZome Therapeutics, NurExone, Ji Yan Biomedical Co., Ltd. and others.
Exosomes Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
Exosomes Products have been categorized under various Molecule types such as,
From emerging drug candidates to competitive intelligence, the Exosomes Pipeline Report @ Exosomes Market Drivers and Barriers, and Future Perspectives
Scope of the Exosomes Pipeline Report
Discover what’s next for the Exosomes Treatment landscape in this detailed analysis @ Exosomes Emerging Drugs and Major Players
Table of Contents
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432City: Las VegasState: https://www.delveinsight.com/report-store/exosomes-pipeline-insightCountry: United StatesWebsite: https://www.delveinsight.com/report-store/exosomes-pipeline-insight
